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This brief data article summarizes the clinical risk factors and laboratory
data of a group of subjects recruited for the AIM-HIGH trial (Athero-
thrombosis Intervention in Metabolic Syndrome with Low HDL/High
Triglycerides and Impact on Global Health Outcomes) and an associated
magnetic resonance imaging (MRI) substudy. The sample is restricted to
those on statin therapy at the time of enrollment and data are pre-
sented stratiﬁed by whether dynamic contrast enhanced MRI (DCE-
MRI) markers of carotid plaque vascularity and inﬂammation were
available or not. The data provided herein are directly related to the
article “Longer Duration of Statin Therapy is Associated with Decreased
Carotid Plaque Vascularity by Magnetic Resonance Imaging” [2].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
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acquiredQuestionnaire, physical examination and fasting blood drawata format Table of statistics
xperimental
factorsSubjects were from the AIM-HIGH trial. All were 45 years or older with
atherogenic dyslipidemia, clinically established cardiovascular disease and cur-
rently on statin therapy.xperimental
featuresAs part of an MRI substudy, some subjects underwent carotid DCE-MRI to assess
vascularity and possible inﬂammation of carotid plaques. Clinical data was
collected prospectively through case report forms and fasting blood draws.ata source
locationSeattle, WA, USAata accessibility The data is presented within this article.D
Value of the data
 These data represent a detailed characterization of this clinically relevant cohort, which is drawn
from a high-risk, secondary prevention population, already treated with statins; one key question
regarding this type question is what other factors can be used to predict residual risk of secondary
cardiovascular events.
 These data can also be used to identify potentially important differences between the carotid DCE-
MRI subsample and the remainder of the cohort which could affect interpretation of results from
DCE-MRI studies based on this cohort.
 Additionally, these data can be used to identify potential factors associated with obtaining usable
or unusable DCE-MRI measurements; this information could be used to reduce exclusions in future
studies.
 Lastly, these data can be used to identify possible subgroups for further analysis or collaboration;
the given sample sizes of subgroups deﬁned by demographics or risk factors are important inputs
for power calculations needed to determine the feasibility of a substudy of this cohort.1. Data
The data presented in this report consist of summaries of clinical atherosclerosis risk factors and
laboratory measurements of the patient population from the AIM-HIGH (Atherothrombosis Intervention
in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial.
Summaries are provided for subgroups based on inclusion in or exclusion from the DCE-MRI substudy [2].2. Experimental design, materials and methods
2.1. Study participants
The data were collected from participants of the AIM-HIGH trial and MRI substudy. The AIM-HIGH
trial inclusion and exclusion criteria have been published previously [1]. Brieﬂy, the primary AIM-
HIGH inclusion criteria included: (1) age 45 years or older, (2) documented stable coronary, cere-
brovascular/carotid or peripheral arterial disease, and (3) “atherogenic dyslipidemia”, deﬁned as HDL-
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cholesterolo180 mg/dL if not taking statin drugs. Only participants on statin therapy and with
known prior duration of treatment were included in this data compilation.
MRI substudy speciﬁc inclusion criteria were: (1) eligible for main AIM-HIGH study, (2) medically
able to undergo MRI procedure, (3) willing to provide informed consent for sub-study participation.
Substudy speciﬁc exclusion criteria were: (1) history of pacemaker or metallic implants, (2) history of
bilateral carotid endarterectomy, or (3) estimated glomerular ﬁltration rate less than 60 mL/min/
1.73 m2. This study was approved by the AIM-HIGH Executive Committee and a local institutional
review board or research ethics committee at each participating clinical site. Separate signed
informed consent was obtained from each participant in this substudy.
2.2. Clinical and laboratory data collection
Demographics (sex, age, race and ethnicity), clinical history (prior statin use, prior niacin use, history of
diabetes) and other atherosclerosis risk factor data (tobacco use, metabolic syndrome, blood pressure,
body mass index) were collected prospectively by a questionnaire and physical examination and were
recorded using case report forms (CRFs). The duration of statin therapy prior to entering the trial was
recorded using the categories o1 year, 1–5 years and 45 years. This categorization was determined by
the AIM-HIGH trial executive committee prior to data analysis in this study. At the baseline examination
to conﬁrm eligibility for the trial, a fasting blood draw was performed. Lipids (triglycerides and total, LDL-,
HDL-cholesterol) and lipoproteins (ApoB, ApoA1 and lipoprotein(a)) were measured from these samples.
2.3. DCE-MRI protocol
The carotid DCE-MRI protocol and image analysis procedures are described in detail elsewhere
[2,3]. Prior to image analysis, participants were excluded if image quality was insufﬁcient to interpret
the images or there was a DCE-MRI protocol violation which prevented proper estimation of the DCE-
MRI parameters. In addition, cases were excluded during the image analysis if the mean carotid vessel
wall thickness was found to be o1 mm due to low reliability of DCE-MRI estimates in this situation.
While DCE-MRI measurement data are not presented here, more information regarding the protocol,
image analysis and reproducibility has been reported [4].
2.4. Statistical methods
Categorical variables were summarized as percentage (count) and continuous variables were
summarized as mean7standard deviation (SD). Clinical and laboratory values were compared
between groups of subjects using Fisher’s exact test (categorical variables) and the Mann–Whitney
test (continuous variables). Three groups (not mutually exclusive) were deﬁned: (1) AIM-HIGH
subjects with DCE-MRI measurements available, (2) subjects who underwent DCE-MRI but did not
have usable measurements, and (3) AIM-HIGH subjects without usable DCE-MRI measurements
available (excludes group 1 but contains group 2). Only subjects on statin therapy at enrollment with
known prior duration were included. All statistical calculations were conducted using R (version
2.14.1; The R Foundation for Statistical Computing, Vienna, Austria). Throughout, two-tailed tests
were used with statistical signiﬁcance deﬁned as po0.05.3. Data tables
Of the 3414 participants randomized in the AIM-HIGH trial, 3101 (91%) were on statin therapy at
entry with known prior duration. Of these, 206 underwent DCE-MRI. After excluding 52 for image
quality issues or protocol violations and 56 for wall thickness below the minimum threshold of 1 mm,
there were 98 subjects available for analysis in the DCE-MRI substudy. Table 1 summarizes the
demographics, clinical status and laboratory data of the 98 DCE-MRI participants and the remainder of
the cohort. Table 2 compares clinical and laboratory data between the 98 DCE-MRI participants with
Table 1
Baseline summary of DCE-MRI, clinical and laboratory data in the DCE-MRI substudy sample and those in the remaining AIM-
HIGH cohort who were on statin therapy at enrollment.
Variable In DCE-MRI substudy P-value
Yes (N¼98) No (N¼2903)
Sex – no. (%) 40.99
Male 84 (86%) 2464 (85%)
Female 14 (14%) 439 (15%)
Age – years 6279 6479 0.072
Racea – no. (%) 0.69
White 90 (92%) 2690 (93%)
Non-white/other 8 (8%) 212 (7%)
Ethnicitya – no. (%) 0.79
Hispanic or Latino 4 (4%) 111 (4%)
Not Hispanic or Latino 93 (96%) 2792 (96%)
Tobacco usea – no. (%) 0.48
Current 21 (21%) 558 (19%)
Former (quit41 year ago) 48 (49%) 1580 (55%)
Never used 29 (30%) 742 (26%)
Duration of statin therapy – no. (%) 0.052
o1 year 21 (21%) 371 (13%)
1–5 years 39 (40%) 1217 (42%)
45 years 38 (39%) 1315 (45%)
Prior use of niacin – no. (%) 15 (15%) 568 (20%) 0.36
Presence of metabolic syndromea –
no. (%)
79 (81%) 2334 (81%) 40.99
History of diabetes – no. (%) 22 (22%) 979 (34%) 0.022
Body mass indexa – kg/m2 3074.1 3175.3 0.005
Systolic blood pressurea – mmHg 129718 128716 0.61
Diastolic blood pressurea – mmHg 75710 74710 0.85
Total cholesterol – mg/dl 139723 144725 0.31
LDL cholesterol – mg/dl 71718 72721 0.95
Non-HDL cholesterol – mg/dl 105721 109724 0.32
Triglycerides – mg/dl 169762 181766 0.037
Lipoprotein(a)a – mg/dl 84790 77789 0.55
ApoBa – mg/dl 82719 82719 0.98
HDL cholesterol – mg/dl 3476.1 3575.6 0.62
ApoA-Ia – mg/dl 119716 124716 0.039
Total:HDL ratio 4.270.8 4.270.9 0.60
ApoB:ApoA-I ratioa 0.770.2 0.770.2 0.17
Unless otherwise speciﬁed, values are no. (%) or means7SD.
a Individuals missing values excluded for comparisons involving that variable, including: race (n¼1), ethnicity (n¼1),
tobacco use (n¼23), metabolic syndrome (n¼9), body mass index (n¼5), systolic blood pressure (n¼2), diastolic blood
pressure (n¼3), lipoprotein(a) (n¼48), apoB (n¼54), apoA-I (n¼54) and apoB:apoA-I ratio (n¼54).
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Table 2
Comparison of baseline variables between those with DCE-MRI measurements and those with DCE-MRI but who were
excluded due to image quality, protocol violations or wall thicknesso1 mm.
Variable DCE-MRI subjectsa P-value
Included
(N¼98)
Excluded
(N¼108)
Sex – no. (%) 0.46
Male 84 (86%) 88 (81%)
Female 14 (14%) 20 (19%)
Age – years 6279 6178 0.30
Raceb – no. (%) 0.026
White 90 (92%) 86 (80%)
Non-white/other 8 (8%) 21 (20%)
Ethnicityb – no. (%) 0.38
Hispanic or Latino 4 (4%) 8 (7%)
Not Hispanic or Latino 93 (96%) 100 (93%)
Tobacco use – no. (%) 0.48
Current 21 (21%) 17 (16%)
Former (quit41 year ago) 48 (49%) 61 (56%)
Never used 29 (30%) 30 (28%)
Duration of statin therapy –
no. (%)
0.76
o1 year 21 (21%) 28 (26%)
1–5 years 39 (40%) 40 (37%)
45 years 38 (39%) 40 (37%)
Prior use of niacin – no. (%) 15 (15%) 22 (20%) 0.37
Presence of metabolic syn-
drome – no. (%)
79 (81%) 87 (81%) 40.99
History of diabetes – no. (%) 22 (22%) 32 (30%) 0.27
Body mass indexb – kg / m2 29.774.1 30.974.8 0.064
Systolic blood pressureb –
mmHg
129718 128717 0.87
Diastolic blood pressureb –
mmHg
75710 7579 0.72
Total cholesterol – mg/dl 139723 141728 0.92
LDL cholesterol – mg/dl 71718 73725 0.91
Non-HDL cholesterol – mg/dl 105721 107728 0.88
Triglycerides – mg/dl 169762 171763 0.78
Lipoprotein(a)b – mg/dl 83.6789.8 73.5792.0 0.41
ApoBb – mg/dl 82.2719.0 82.5721.4 0.97
HDL cholesterol – mg/dl 34.376.1 34.975.2 0.62
ApoA-Ib – mg/dl 118.9716.4 123.9716.7 0.10
Total:HDL ratio 4.270.8 4.171.1 0.67
ApoB:ApoA-I ratiob 0.770.2 0.770.2 0.29
Unless otherwise speciﬁed, values are no. (%) or means7SD.
a Only includes those already on statins at enrollment with known prior duration.
b Individuals missing values excluded for comparisons involving that variable, including: race (n¼1), ethnicity (n¼1), body
mass index (n¼1), systolic blood pressure (n¼1), diastolic blood pressure (n¼1), lipoprotein(a) (n¼2), apoB (n¼2), apoA-I
(n¼2) and apoB: apoA-I ratio (n¼2).
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